BEN VENUE TO DISTRIBUTE LIMITED METHOTREXATE SUPPLIES
A Message About Bedford Laboratories‘ Methotrexate
To answer the urgent need for Bedford Laboratories’ methotrexate, Ben Venue Laboratories (Ben Venue) has been actively working with the U.S. Food and Drug Administration (FDA) to expedite the availability of preservative-free methotrexate for injection USP (in both liquid and lyophilized formulations). As a result, Ben Venue has accelerated the review process and will immediately begin releasing a limited supply of methotrexate. This supply was produced before Ben Venue voluntarily suspended manufacturing of all products in November 2011 to address manufacturing-related issues at its facility.
Product will be allocated to oncology clinics, hospitals and pediatric facilities beginning Thursday, February 16, 2012 and will continue over the next several weeks. We hope this supply will help address near-term patient needs while other companies licensed to manufacture methotrexate increase production.